Ultimovacs ASA announced that the company’s universal cancer vaccine, UV1, will be investigated in a new Phase II clinical trial in combination with pembrolizumab in NSCLC.
[Ultimovacs ASA]
6445212
AAAAAAAA
items
1
apa
0
default
asc
1
168254
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
